James J Peters VA Medical Center

Summary

James J Peters VA Medical Center is a medical facility located in Bronx, New York. This center is recognized for care of Spinal Cord Injury, Lung Cancer, Prostate Cancer, Post-Traumatic Stress Disorder, Cervical Cord Injury and other specialties. James J Peters VA Medical Center is involved with conducting 219 clinical trials across 288 conditions. There are 32 research doctors associated with this hospital, such as Gary Schwartz, MD, Susan E. Bates, Jill M Wecht, EdD, and Yeun-Hee A. Park.

Top PIs

Clinical Trials running at James J Peters VA Medical Center

Prostate Cancer

Spinal Cord Injury

Lung Cancer

Suicide

Post-Traumatic Stress Disorder

Depression

Low Blood Pressure

Non-Small Cell Lung Cancer

Cancer

Obsessive-Compulsive Disorder

Pembrolizumab

for Prostate Cancer

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.

Recruiting

2 awards

Phase 2

3 criteria

Opevesostat

for Prostate Cancer

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.

Recruiting

2 awards

Phase 3

10 criteria

PF-06821497 + Enzalutamide

for Prostate Cancer

Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.

Recruiting

2 awards

Phase 3

5 criteria